Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease.
Boucault L, Lopez Robles MD, Thiolat A, Bézie S, Schmueck-Henneresse M, Braudeau C, Vimond N, Freuchet A, Autrusseau E, Charlotte F, Redjoul R, Beckerich F, Leclerc M, Piaggio E, Josien R, Volk HD, Maury S, Cohen JL, Anegon I, Guillonneau C.
Boucault L, et al. Among authors: braudeau c.
Blood Adv. 2020 Jun 9;4(11):2501-2515. doi: 10.1182/bloodadvances.2020001688.
Blood Adv. 2020.
PMID: 32511714
Free PMC article.